J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, R
Right arrow Articles by Balian, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, R
Right arrow Articles by Balian, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

R Yuan, DA Flockhart, and JD Balian

This review was conducted to identify the current data on drug interactions with alprazolam, midazolam, and triazolam to guide practitioners in the use of these drugs. The Medline electronic database from 1966 through 1998 was used to identify clinical studies of the pharmacokinetic effect of drugs on these three benzodiazepines. Of a total of 491 literature reports identified, 59 prospective studies met our selection criteria. The pharmacokinetic parameters of AUC, Cmax, t1/2, and tmax were evaluated for changes following an interaction. To allow comparison between studies, changes in the parameters were normalized relative to the control values. Pharmacodynamic effects and measures, when reported in the original studies as statistically significant, were classified as a strong interaction, and when the interaction was present but not statistically significant, they were classified as mild in this review. As a result, clinically significant drug interactions were noted for all three benzodiazepines, although it is clear that statistically significant pharmacokinetic changes do not always translate into clinically significant pharmacodynamic consequences. All three benzodiazepines were susceptible to drug interactions, but oral dosing of midazolam and triazolam resulted in greater alterations in the pharmacokinetic parameters than alprazolam due to their larger presystemic extraction. Ketoconazole and itraconazole were found to be the most potent metabolic inhibitors that prolonged the duration of or intensified the magnitude of the dynamic response produced by the three benzodiazepines. Rifampin, carbamazepine, and phenytoin were noted to be potent metabolic inducers, and their treatments result in loss of benzodiazepine therapeutic efficacy. In conclusion, potent metabolic inhibitors and inducers can either significantly prolong or diminish the dynamic effects of benzodiazepines via their influence on the pharmacokinetics of benzodiazepines.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
American Academy of Pediatrics, American Academy of Pediatric Dentistry, C. J. Cote, S. Wilson, and the Work Group on Sedation
Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures: An Update
Pediatrics, December 1, 2006; 118(6): 2587 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
L. Z. Benet
There Are No Useful CYP3A Probes that Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and No Expectation that One Will Be Found
Mol. Interv., April 1, 2005; 5(2): 79 - 83.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. E. Martin, S. R. Howell, L. L. Martin, I. Cirillo, and J. S. Barrett
No Clinically Relevant CYP3A Induction with the Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240
J. Clin. Pharmacol., April 1, 2004; 44(4): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kotegawa, B. E. Laurijssens, L. L. von Moltke, M. M. Cotreau, M. D. Perloff, K. Venkatakrishnan, J. S. Warrington, B. W. Granda, J. S. Harmatz, and D. J. Greenblatt
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1228 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. J. Cote, I. T. Cohen, S. Suresh, M. Rabb, J. B. Rose, B. C. Weldon, P. J. Davis, G. B. Bikhazi, H. W. Karl, K. A. Hummer, et al.
A Comparison of Three Doses of a Commercially Prepared Oral Midazolam Syrup in Children
Anesth. Analg., January 1, 2002; 94(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. A. C. 't Hoen, M. K. Bijsterbosch, T. J. C. van Berkel, N. P. E. Vermeulen, and J. N. M. Commandeur
Midazolam Is a Phenobarbital-Like Cytochrome P450 Inducer in Rats
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 921 - 927.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology